Format

Send to

Choose Destination
Expert Rev Vaccines. 2004 Jun;3(3):249-67.

A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine.

Author information

1
Unit of Epidemiology and Social Medicine, Centre for the Evaluation of Vaccination, WHO Collaborating Centre for the Prevention and Control of Viral Hepatitis, University of Antwerp, Campus 3 Eiken, Wilrijk, Belgium. pierre.vandamme@ua.ac.be

Abstract

Hepatitis A and B are two of the most common vaccine-preventable liver diseases and continue to be a significant cause of morbidity and mortality worldwide, with their severity related to the individual's age upon initial infection. Twinrix (GlaxoSmithKline), a combined vaccine providing protection against both hepatitis A and B, has been available in more than 72 countries worldwide since 1997. This paper provides a critical review of clinical data on the efficacy, immunogenicity and tolerability of the combined vaccine, with particular focus on the clinical benefits of dual vaccination.

PMID:
15176942
DOI:
10.1586/14760584.3.3.249
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center